Dr Chari on the Safety Profile of Talquetamab in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, director, discusses the safety profile of talquetamab following the drug’s FDA approval for patients with relapsed/refractory multiple myeloma.

Related Keywords

New York ,United States , ,Myeloma Program ,Icahn School Of Medicine At Mount Sinai ,Helen Diller Family Comprehensive Cancer Center ,Ajai Chari ,Multiple Myeloma Program ,Diller Family Comprehensive Cancer Center ,Icahn School ,Mount Sinai ,Ucsf Helen Diller Family Comprehensive Cancer Center ,Onclive Tv ,Multiple Myeloma ,